ESMO / ECC Conference Coverage

Here’s a Hypothesis: Lower Doses Of Some Cancer Pills Could Save A Lot Of Money

(STAT Plus/Pharmalot) Oct 23, 2018 - What would you say if a cancer patient could be given a lower dose of a pricey treatment that was not only equally effective, but could also save a bundle of money? That’s the proposition being advanced by some leading oncologists, who are promoting what they call value-based prescribing, which involves giving patients fewer or less frequent doses. The notion is being increasingly talked up as concerns mount over the rising cost of medicines and, consequently, the so-called financial toxicity that more patients are said to be experiencing.

read article (paid subscription required)

ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front

(Xconomy National) Oct 23, 2018 - The European Society for Medical Oncology is wrapping up its annual conference today, replete with clinical data from cancer’s front lines. We’ve sorted the headlines into a few big categories: immunotherapy combinations, breast cancer, lung cancer, the growing class of drugs called PARP inhibitors, and new drugs that treat tumors based on genetic signature. Patients with two different types of breast cancer got promising news at ESMO from studies exploring relatively new methods of treatment. Drugs that boost a patient’s immune system to fight back against cancer have been approved to fight several types of cancer and have even become a first-line option against some advanced lung and kidney cancers. But experimental results unveiled over the weekend are the first in immunotherapy to show a survival benefit in breast cancer, which causes the second-most cancer deaths among U.S. women.

read article

Barriers To Early Clinical Trial Access For Adolescents And Young Adults Still Exist, Study Shows

(ESMO 2018 Congress) Oct 21, 2018 - Arbitrary age limits for participation prevent young patients from entering trials designed for their tumour type.

read press release

Oncologists Demand More Education On The Use Of Biosimilars: ESMO Takes Action

(ESMO 2018 Congress) Oct 20, 2018 - Biological medicines are responsible for some of the most promising innovations in cancer treatment, including immunotherapy, targeted drugs and vaccines – but they are also expensive.

read press release

Immunotherapy Is Safe And Feasible In Cancer Patients Treated For HIV, Study Suggests

(ESMO 2018 Congress) Oct 20, 2018 - Immunotherapy has been a major breakthrough in oncology, with registered drugs now approved for use in an increasing number of tumour types – but little is known about its safety for HIV-positive cancer patients.

read press release

New Research Shows Benefits Of Exercise For First Time In Advanced Lung Cancer

(ESMO 2018 Congress) Oct 20, 2018 - Most people with lung cancer are unaware of the benefits of regular exercise, yet new data show it can significantly reduce fatigue and improve well being. Results of two studies to be presented at the ESMO 2018 Congress in Munich (1,2) underline the value of exercise, including in patients with advanced or metastatic lung cancer.

read press release

Drugs For Treating Breast Cancer In Women Are Effective And Well Tolerated In Men

(ESMO 2018 Congress) Oct 21, 2018 - There is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated in men, according to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer (1) and two further studies reported at ESMO 2018 Congress.

read press release

TESARO Announces Data Presentations at ESMO 2018 Congress

(NASDAQ) Oct 20, 2018 - Data presented indicate that TSR-042 (anti-PD-1 antibody) is well tolerated and has robust activity in patients with MSI-H endometrial cancer; PRIMA safety data for individualized niraparib dose regimen presented; Top-line results for PRIMA trial of niraparib in first-line ovarian cancer regardless of biomarker status expected in late 2019.

read article

Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma

(Exelixis) Oct 22, 2018 - Combination of cabozantinib and atezolizumab is well tolerated and shows promising anti-tumor activity; safety and efficacy data support 18 expansion cohorts evaluating the combination in 12 different tumor types.

read corporate press release

Merck KGaA, Darmstadt, Germany, Presents Updated Results for Bifunctional Immunotherapy M7824 at ESMO 2018 Congress

(Merck KGaA) Oct 22, 2018 - New data include first disclosure of results for M7824 in advanced squamous cell carcinoma of the head and neck, biliary tract cancer and esophageal cancers; updated data also being presented include non-small cell lung cancer and gastric cancer; M7824 is a bifunctional immunotherapy designed to bring together transforming growth factor-β and anti-PD-L1 mechanisms.

read corporate press release

QED Therapeutics Presents Data for Infigratinib in Cholangiocarcinoma in Late Breaking Abstract at the European Society of Medical Oncology 2018 Congress

(The Business Journals) Oct 19, 2018 - QED Therapeutics today announced the presentation of positive, updated interim data of infigratinib (BGJ398), an orally administered, selective fibroblast growth factor receptor (FGFR) 1-3 tyrosine kinase inhibitor, for the treatment of advanced or metastatic cholangiocarcinoma (bile duct cancer) during a late-breaking poster discussion at the European Society for Medical Oncology (ESMO).

read article

Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab) Continues to Show a 70% Overall Response Rate in Advanced Melanoma Patients According to Data Presented Today at the ESMO 2018 Congress

(Dynavax) Oct 20, 2018 - Dynavax Technologies Corporation today presented interim data from its ongoing Phase 1b/2 SYNERGY-001 study investigating SD-101, Dynavax's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck (known as MSD outside the United States and Canada) in patients with advanced melanoma naïve to anti-PD-1/L1 therapy.

read corporate press release

Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma

(NASDAQ) Oct 21, 2018 - Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.

read article

Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC

(Kura Oncology) Oct 22, 2018 - Kura Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today reported updated preliminary results from a Phase 2 clinical trial of its lead product candidate, tipifarnib, in squamous cell carcinomas with HRAS mutations.

read corporate press release

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Results in Significantly Longer Treatment-Free Survival in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

(BMS) Oct 22, 2018 - Bristol-Myers Squibb Company today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) was associated with significantly longer treatment-free survival (TFS).

read corporate press release

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Durable Four-Year Survival Benefits in Patients with Advanced Melanoma

(BMS) Oct 22, 2018 - Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial – the longest follow-up to date – which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

read corporate press release

Details of Study That Led to Radium-223 Restriction in Europe

(Medscape Medical News) Oct 20, 2018 - Details of the ERA 223 clinical trial that led to a restriction in Europe of the use of the radiopharmaceutical radium-223 dichloride (Ra-223; Xofigo, Bayer) have now been presented here at the European Society for Medical Oncology (ESMO) 2018 Congress.

read article (free registration required)

Palbociclib in Breast Cancer: New Overall Survival Data

(Medscape Medical News) Oct 21, 2018 - The new class of cyclin-dependent kinase (CDK) 4/6 inhibitors offer hope for patients with advanced breast cancer who have stopped responding to endocrine therapy.

read article (free registration required)

Roche Takes On Loxo, Bayer In Gene-Defined Cancer Class

(Reuters) Oct 21, 2018 - Roche’s entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified via genetic profiling, as the Swiss drugmaker challenges an alliance of Bayer and Loxo Oncology in a new targeted treatment area. The trial results on patients with a gene anomaly known as NTRK fusion, which occurs in less than 1 percent across a range of tumor types, were presented at the annual congress of the European Society for Medical Oncology (ESMO) in Munich on Sunday. Germany’s Bayer and U.S. partner Loxo, in turn, released data for their rival compound larotrectinib, which slightly improved on previous high-efficacy readings in an enlarged trial.

read article

Immunotherapy Scores a First Win Against Some Breast Cancers

(Associated Press) Oct 20, 2018 - For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. Results were discussed Saturday at a cancer conference in Munich and published by the New England Journal of Medicine. Drugs called checkpoint inhibitors have transformed treatment of many types of cancer by removing a chemical brake that keeps the immune system from killing tumor cells. Their discovery recently earned scientists a Nobel Prize. Until now, though, they haven’t proved valuable against breast cancer.

read article
Next Page